Norepinephrine reuptake inhibitors (NRIs), also known as noradrenaline reuptake inhibitors (NARIs), are compounds that elevate the extracellular level of the neurotransmitter norepinephrine in the CNS by inhibiting its reuptake from the synaptic cleft into the presynaptic neuronal terminal via the norepinephrine transporter. Virtually, they do not act at other monoamine transporters.

List of NRIs

• Atomoxetine (Strattera^®)
• Reboxetine (Edronax^®)
• Viloxazine (Vivalan^®)
• Maprotiline (Ludiomil^®)

Strattera^® is available in the United States and is indicated by the Food and Drug Administration (FDA) for the treatment of ADD and ADHD, off-label uses include the treatment of depression, and anxiety.

Reboxetine, unavailable in the United States and Canada, has been found to be effective at combating depression.

Antidepressants

Selektiver Noradrenalin-Wiederaufnahmehemmer | SNRI